The investigators investigated the point mutations in the 23S rRNA genes of patients infected with clarithromycin-resistant H. pylori and compared the H. pylori eradication rates based on the identified clinically significant point mutations.

NCT03884348

Conditions

1. Helicobacter Pylori Infection
2. Antibiotic Resistant Strain

Interventions

1. Drug: proton pump inhibitor, amoxicillin, clarithromycin
2. Drug: proton pump inhibitor, amoxicillin, metronidazole

MeSH:Sprains and Strains

Inclusion Criteria: - Clinical diagnosis of Helicobacter pylori infection Exclusion Criteria: - H. pylori eradication therapy within 1 year, - antibiotics within 4 weeks, - surgery for gastric cancer - malignant tumors other than gastric cancer - end-stage renal disease - liver cirrhosis, - pregnancy Inclusion Criteria: - Clinical diagnosis of Helicobacter pylori infection Exclusion Criteria: - H. pylori eradication therapy within 1 year, - antibiotics within 4 weeks, - surgery for gastric cancer - malignant tumors other than gastric cancer - end-stage renal disease - liver cirrhosis, - pregnancy Helicobacter Pylori Infection Antibiotic Resistant Strain Sprains and Strains Sequencing-based detection of point mutations identified four mutations that were considered clinically significant (A2142G, A2142C, A2143G, A2143C), while all the other mutations were considered clinically insignificant. --- A2142G --- --- A2142C --- --- A2143G --- --- A2143C ---